Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507911 | SCV001713751 | uncertain significance | not provided | 2020-09-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002488305 | SCV002793091 | uncertain significance | Age related macular degeneration 9; Atypical hemolytic-uremic syndrome with C3 anomaly; Complement component 3 deficiency | 2022-05-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001507911 | SCV002981227 | uncertain significance | not provided | 2022-02-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 1636 of the C3 protein (p.Glu1636Gln). This variant is present in population databases (rs139388954, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with C3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1163114). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). |
Diagnostic Laboratory, |
RCV001507911 | SCV001743325 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001507911 | SCV001975153 | uncertain significance | not provided | no assertion criteria provided | clinical testing |